MALVERN, Pa., SEP 21, 2023 — LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTAC, molecular glue drug discovery and neurodegeneration diagnostics has been invited to speak at the 21st annual Discovery on Target 2023. Dr. Karteek Kadimisetty, LifeSensors’ Director of Research and Development will be presenting new information, and answering questions regarding PROTACs, Molecular Glues, and the future of Drug Discovery from the 25th of September to the 28th in Boston, Massachusetts. Find out more here.
LifeSensors has simplified the discovery of molecular glue degraders. Given the challenges of PROTACs medicinal chemistry, target engagement in human clinical trials and DMPK issues, LifeSensors has developed new approaches to discover molecular glue degraders that will be more rewarding. Dr. Kadimisetty, Director of R& D will disclose new technologies that will facilitate rapid discovery and development of molecular glue degraders. The challenges and new developments in the field of ligand mediated ubiquitination will be discussed.
The LifeSensors Research and Development team will be presenting through their exhibition booth #310 at Discovery on Target from September 25th to September 28th at the Sheraton in Boston. Please stop LifeSensors’ booth to discuss more about PROTACs, Molecular Glues, and the future of Drug Discovery. Please contact us about your molecular glue and PROTAC projects here.
Join us at our presentations:
Poster 1: Beyond Protein Degradation: Studying Ubiquitination to Advance TPD Drug Discovery, Presented by Karteek Kadimisetty, LifeSensors, Inc.
Poster 2: Unlocking Targeted Protein Degradation: Discovery of Unique E3 Ligands, Presented by Janelle Pedroza, LifeSensors, Inc.
Presentation: Beyond Protein Degradation: Studying Ubiquitination to Advance TPD Drug Discovery, Presented by Karteek Kadimisetty, LifeSensors, Inc.
Tuesday, September 26, 2:35pm
About LifeSensors, Inc.
LifeSensors, Inc. partners with pharma and biotech companies to help life scientists innovate in basic research, drug discovery and diagnostics. We pioneered the SUMO-fusion system to measure high quality protein expression. Our development of cutting-edge tools for the ubiquitin proteasome system (UPS) and Protein Targeting Chimeras (PROTAC) gives scientists new tools to observe and test the fundamentals of this emerging area in medicine. Poly-ubiquitin affinity matrices, Tandem Ubiquitin Binding Entities (TUBES), are changing the way scientists make discoveries in UPS and how they identify new biomarkers for neurodegeneration and drug discovery.
We are making an impact in the lives of scientists through innovation and pushing the envelope with regards to novel research techniques not only in PROTAC technology, but in the growing and highly applicable areas of Molecular Glues and other technologies regarding the ubiquitin proteasome system.
Contact: Isabelle Wentzel
(610) 644-8845 EXT. 304